Loading...
XTAI
4142
Market cap253mUSD
Oct 08, Last price  
19.20TWD
1D
3.50%
1Q
8.78%
Jan 2017
-11.49%
IPO
-48.14%
Name

Adimmune Corp

Chart & performance

D1W1MN
XTAI:4142 chart
P/E
—
P/S
5.77
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.52%
Rev. gr., 5y
-5.60%
Revenues
1.40b
-9.99%
223,540,000182,335,0001,369,929,000834,775,000290,363,000387,162,000414,093,000480,506,000290,737,000606,725,000562,743,000822,366,0001,299,689,0001,869,147,0001,641,061,0002,251,624,0001,785,094,0001,556,989,0001,401,501,000
Net income
-240m
L-1.18%
-34,302,000-72,450,000588,882,000161,307,000-471,318,000-603,680,000-600,453,000-614,422,000-761,087,000-595,352,000-760,176,000-617,843,000-280,678,0001,241,246,00043,066,000290,975,000-639,891,000-242,750,000-239,889,000
CFO
-5m
L
31,260,000-135,691,000600,423,000516,393,000-293,775,000-409,475,000-568,636,000-417,354,000-373,817,000-773,530,0006,874,000-601,740,000-252,723,0002,321,723,000-480,517,000-291,965,000-892,349,000668,481,000-5,446,000
Dividend
Sep 14, 20210.5 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Adimmune Corporation, a Taiwanese pharmaceutical company, specializes in the production and distribution of human vaccines. Its comprehensive product portfolio includes a range of critical immunizations. Key offerings feature the quadrivalent influenza vaccine, AdimFlu-S, alongside trivalent influenza vaccines and the Influenza A (H1N1) Virus Monovalent Vaccine. The company also provides tetanus toxoid products, vital for post-injury tetanus prevention, and Japanese encephalitis vaccines. Furthermore, Adimmune supplies purified Tuberculin and extends its expertise through contract manufacturing services. Established in 1965, the company initially operated under the name Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. It subsequently rebranded as Adimmune Corporation in 2001 and maintains its headquarters in Taichung, Taiwan.

Key people

Chin-Chuan Chang
Chief Operating Officer · since 2019
Chi-Shean Chan
Chairman of the Board, General Manager · since 2025
Jin-Yi Chiou
Deputy General Manager-Quality Assurance Division · since 2012
Yueh-Peng Hung
Deputy General Manager-Business Division · since 2023
Fei Pan
Deputy General Manager, Chief Legal Officer · since 2012
Hui-Wen Wang
Deputy General Manager-New Technology and Process Development Division · since 2023
Hui-yi Lai
Head of Accounting · since 2025
Jing-Yao Lin
Corporate Governance Officer · since 2021
Yuan-Hou Yen
Deputy Chief Operating Officer · since 2007
Jung-Chin Lin
Director · since 2019
Jong-Rong Lin
Director · since 2025
Chi-Heng Lin
Director · since 2019
Te-Sheng Lin
Director · since 2023
Xunyu Liu
Director · since 2026
Chung-Cheng Liu
Director · since 2025
Chin-Wen Yang
Director · since 2025
Pei-Jun Hong
Independent Director · since 2025
Mei-Ling Hsiao
Independent Director · since 2024
Yung-Sheng Hsu
Independent Director · since 2020
Hsiao-Po Hsu
Independent Director · since 2011
URL
https://www.adimmune.com.tw/
IPO date
Sep 29, 2010
Employees
Domiciled in
TW
Incorporated in
TW
Headquarters & legal address
NO. 3, SEC. 1, TANXING RD., TANZI DIST.
TAICHUNG, TXG 42743
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT